Alumis eyes as much as $316 million in rare biotech IPO

The company plans on starting a late-stage clinical trial of its drug in the second half of this year in psoriasis patients.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks